Literature DB >> 28266706

Multiple cutaneous leiomyomas leading to discovery of novel splice mutation in the fumarate hydratase gene associated with HLRCC.

Rachel Yi Ping Tan1, Maie Walsh1, Anne Howard2, Ingrid Winship3.   

Abstract

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare autosomal dominant condition, which manifests as cutaneous leiomyomas (CL), uterine fibroids and renal cell cancer (RCC). We describe the case of a 53-year-old woman who presented with multiple CL with a novel heterozygous canonical splice site mutation in intron 9 of the fumarate hydratase (FH) gene IVS 9-1 G>C (NM_000143.3:c 1391-1 G>C) that was not detected on initial screening of a mutation hotspot but was picked up on sequencing the remaining exons and splice site junctions. This report highlights the importance of clinical suspicion in the diagnosis of HLRCC in the absence of a family or personal history of cancer and despite initial genetic testing being negative.
© 2017 The Australasian College of Dermatologists.

Entities:  

Keywords:  cutaneous leiomyoma; fumarate hydratase; hereditary leiomyomatosis and renal cell cancer; renal cell cancer; splice site mutation

Mesh:

Substances:

Year:  2017        PMID: 28266706     DOI: 10.1111/ajd.12605

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  2 in total

1.  An Aggressive Clinical Presentation of Familial Leiomyomatosis Associated with a Fumarate Hydratase Gene Variant of Uncertain Clinical Significance.

Authors:  Federica Scarfi; Ana Paula Orozco; Alessia Visconti; Veronique Bataille
Journal:  Acta Derm Venereol       Date:  2020-07-02       Impact factor: 3.875

Review 2.  The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer.

Authors:  Dimakatso Alice Senthebane; Arielle Rowe; Nicholas Ekow Thomford; Hendrina Shipanga; Daniella Munro; Mohammad A M Al Mazeedi; Hashim A M Almazyadi; Karlien Kallmeyer; Collet Dandara; Michael S Pepper; M Iqbal Parker; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.